Live Breaking News & Updates on Rafael Amado|Page 7

Stay updated with breaking news from Rafael amado. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma

Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Chris Wack , Rafael Amado , Allogene Therapeutics Inc , Dow Jones Company Inc , Drug Administration , Regenerative Medicine Advanced Therapy , Largeb Cell , Fast Track , Dow Jones ,

Allogene FDA Grants RMAT Designation to Allogene's ALLO-501A for Large B Cell Lymphoma

Allogene FDA Grants RMAT Designation to Allogene's ALLO-501A for Large B Cell Lymphoma
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United States , Rafael Amado , American Society Of Hematology , Drug Administration , Regenerative Medicine Advanced Therapy , American Society , Effector Cell Associated Neurotoxicity Syndrome , Century Cures Act , Fast Track ,

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Buy" by Brokerages

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) have earned a consensus recommendation of “Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price […] ....

United States , Hong Kong , Raymond James , Rafael Amado , Robertw Baird , William Blair , Interocean Capital Group , Allspring Global Investments Holdings , Penserra Capital Management , Securities Exchange Commission , Allogene Therapeutics Inc , Goldman Sachs Group , Hong Kong Ltd , Allogene Therapeutics , Get Rating , General Counsel Veer Bhavnagri , Exchange Commission , Global Investments Holdings , Kong Ltd , Capital Management , Ocean Capital Group , Virginia Retirement Systems , Nasdaq Allo ,

Robert W. Baird Begins Coverage on Allogene Therapeutics (NASDAQ:ALLO)

Research analysts at Robert W. Baird started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set a “neutral” rating on the stock. Several other equities research analysts also recently issued reports on the company. Raymond James dropped their price objective on […] ....

United States , Hong Kong , Raymond James , Rafael Amado , Robertw Baird , William Blair , Alison Moore , Allogene Therapeutics Inc , Goldman Sachs Group Inc , Manufacturers Life Insurance Company , Allogene Therapeutics Company Profile Get Rating , Delphia United States Inc , Hong Kong Ltd , Allogene Therapeutics , Get Rating , Kong Ltd , Sachs Group , Therapeutics Company Profile , Nasdaq Allo , Initiated Coverage ,

Zacks: Analysts Expect Allogene Therapeutics, Inc. (NASDAQ:ALLO) Will Post Earnings of -$0.61 Per Share

Analysts expect Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) to report ($0.61) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.67). Allogene Therapeutics reported earnings per share of ($0.53) in the same quarter […] ....

Raymond James , Rafael Amado , William Blair , Morgan Stanley , Primecap Management Co , Allogene Therapeutics Inc , Goldman Sachs Group Inc , Zacks Investment Research , Norges Bank , Allogene Therapeutics , Get Rating , Allogene Therapeutic , General Counsel Veer Bhavnagri , Street Corp , Sachs Group , Nasdaq Allo ,